Issues in hypertension: Drug tolerability and special populations

American Journal of Hypertension

Volumn 14, Issue 7 II, 2001, Pages

  Gavras, Haralambos P ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

Adherence; Angiotensin receptor blocker; Antihypertensive treatment; Hypertension; Tolerability

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; LIPID; LOSARTAN; PLACEBO;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0034968894     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0895-7061(01)02132-x     Document Type: Conference Paper

References (33)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2. Trends in prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960-1991
3. Risk factors in hypertension
4. Metabolic adverse reactions to diuretics. Clinical relevance to elderly patients
5. Tolerability, safety, and quality of life and hypertensive therapy: The case for low-dose diuretics
6. Health outcomes associated with antihypertensive therapies used as first-line agents
7. Hyperlipidemia of diuretic therapy
8. Increased prescribing of antidepressants subsequent to β-blocker therapy
9. β-Blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia
10. Induction of insulin resistance by beta-blockade but not ACE-inhibition: Long-term treatment with atenolol or trandolapril
11. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
12. Results of the fosinopril amlodipine cardiovascular events trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM)
13. Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial
14. What does the future hold for ACE inhibitors?
15. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism
16. Racial differences in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities)
17. Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction
18. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes
19. ACE inhibitor ramipril is more effective than the β-blocker atenonol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardio-protective evaluation) study
20. Eprosartan
21. Eprosartan. A review of its use in the management of hypertension
22. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: Results from a 26-week, double-blind, multicentre study
23. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
24. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
25. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension
26. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems
27. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
28. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: Subgroup analysis of a 26-week, double-blind, multicentre study
29. Comparison of the efficacy of eprosartan and enalapril in patients with severe hypertension
30. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients
31. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers